Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of TQB2916 injection combined with chemotherapy or penpulimab in advanced solid tumors
CTR20242162Phase 2Terminated
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2916 in soft tissue sarcoma (STS), melanoma, malignant solid tumor, sponsored by Nanjing Shunxin Pharmaceutical. Started Jun 2024; status: terminated.
02
Drugs
TQB2916
03
Conditions
soft tissue sarcoma (STS)melanomamalignant solid tumor
Beyond the preview
Go deeper on CTR20242162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242162.